Pathstone Family Office’s AbCellera Biologics ABCL Stock Holding History

Pathstone Family Office’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$80K	Buy	17,390 +2,466	+17%	+$15K	﹤0.01%	1604
2023 Q2	$96.4K	Sell	14,924 -902	-6%	-$6.16K	﹤0.01%	1192
2023 Q1	$119K	Sell	15,826 -19,350	-55%	-$176K	﹤0.01%	1123
2022 Q4	$356K	Sell	35,176 -724	-2%	-$8.36K	﹤0.01%	1209
2022 Q3	$356K	Buy	35,900 +17,205	+92%	+$189K	﹤0.01%	1183
2022 Q2	$199K	Buy	18,695 +4,177	+29%	+$35.4K	﹤0.01%	964
2022 Q1	$142K	Buy	14,518 +1,425	+11%	+$13.5K	﹤0.01%	915
2021 Q4	$187K	Buy	13,093 +1,100	+9%	+$16.7K	﹤0.01%	843
2021 Q3	$240K	Buy	+11,993	New	+$212K	0.01%	749

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Pathstone Family Office's ABCL Position: Q3 2023 in Review

Pathstone Family Office increased its AbCellera Biologics (ABCL) stake by 17% in Q3 2023, buying an estimated $15K and bringing the position to 17,390 shares worth $80K. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

Pathstone Family Office first reported a position in ABCL in Q3 2021 and has held it in 9 quarters since. The position peaked at $356K in Q4 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

Pathstone Family Office held 17,390 shares of AbCellera Biologics worth $80K as of Q3 2023.
Pathstone Family Office bought 2,466 AbCellera Biologics shares in Q3 2023, an estimated $15K.
AbCellera Biologics made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1604 holding.
Pathstone Family Office first reported a position in AbCellera Biologics in Q3 2021 and has held it in 9 quarters since.
Pathstone Family Office's AbCellera Biologics position peaked at $356K in Q4 2022.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.